SkinBioTherapeutics Plc
SBTX.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.69 | 0.56 | 2.15 | -0.14 |
| FCF Yield | -3.41% | -17.44% | -13.65% | -8.72% |
| EV / EBITDA | -175.51 | -6.17 | -6.56 | -10.19 |
| Quality | ||||
| ROIC | -7.48% | -67.63% | -132.92% | -108.23% |
| Gross Margin | 58.33% | 56.50% | 64.51% | 60.64% |
| Cash Conversion Ratio | 1.82 | 0.92 | 0.93 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 227.49% | 152.88% | – | – |
| Free Cash Flow Growth | 55.40% | -4.06% | -1.46% | -66.12% |
| Safety | ||||
| Net Debt / EBITDA | 19.26 | -0.01 | 0.41 | 0.57 |
| Interest Coverage | -8.99 | -56.52 | -337.54 | -294.24 |
| Efficiency | ||||
| Inventory Turnover | 2.42 | 1.11 | 1.40 | 0.24 |
| Cash Conversion Cycle | 165.23 | 235.87 | -1,249.88 | 682.74 |